1. Thoumi FE. Illegal drugs, economy, and society in the Andes. Washington, D.C.: Woodrow Wilson Center Press; 2003.
2. Spillane JF. Cocaine: from medical marvel to modern menace in the United States, 1884–1920. Baltimore: Johns Hopkins University Press; 2000.
3. Musto DF. The American disease: origins of narcotic control. 3rd ed. New York: Oxford University Press; 1999.
4. Reinarman C, Levine HG, editors. Crack in America: demon drugs and social justice. Berkeley and Los Angeles: University of California Press; 1997.
5. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. Journal of the History of Medicine and Allied Sciences. 2006;61(3):288–323. [PubMed]
6. Goode E. Drugs in American society. 6th ed. New York: McGraw-Hill; 2005.
7. Hunt D, Kuck S, Truitt L. Methamphetamine Use: Lessons Learned, final report to the National Institute of Justice 2006. 2006. Feb, (NCJ 209730)
10. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434) Rockville, MD: 2009.
11. Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992–2007. Drug Alcohol Rev. 2008 May;27(3):229–235. [PubMed]
12. Substance Abuse and Mental Health Services Administration OoAS. Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339. Rockville, MD: 2008. 2008.
13. Substance Abuse and Mental Health Services Administration OoAS. Drug Abuse Warning Network, 2007: Area Profiles of Drug-Related Mortality. HHS Publication No. SMA 09-4407, DAWN Series D-31. Rockville, MD: 2009. 2009.
14. Nicosia N, Pacula RL, Kilmer B, Lundberg R, J C. The economic cost of methamphetamine use in the United States, 2005. Santa Monica: RAND Drug Policy Research Center; 2009. 2009.
15. United Nations Office on Drugs and Crime. 2009 World Drug Report. Vienna: 2009.
16. Hatsukami DK, Fischman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996 Nov 20;276(19):1580–1588. [PubMed] 18. Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sciences. 2000;67(12):1507–1515. [PubMed] 20. Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med. 1991;9:336–342. [PubMed] 21. Kinzie E. Levamisole found in patients using cocaine. Ann Emerg Med. 2009 Apr;53(4):546–547. [PubMed] 22. Knowles L, Buxton JA, Skuridina N, et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct J. 2009;6:30. [PMC free article] [PubMed]
24. US Department of Justice, National Drug Intelligence Center. National Drug Threat Assessment 2009. Washington, DC: 2008.
25. US Department of Justice, National Drug Intelligence Center. National Methamphetamine Threat Assessment 2007. Washington, DC: 2006.
26. Ellenhorn MJ, Schonwald S, Ordog G, et al. Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning. 2nd ed. ed. Baltimore: Williams and Wilkins; 1997.
27. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002;21(1):21–34. [PubMed] 28. Schifano F, Corkery JM, Cuffolo G. Smokable (“ice”, “crystal meth”) and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. Ann Ist Super Sanità 2007;43(1):110–115. [PubMed] 29. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am. 1996 Sep;19(3):515–547. [PubMed]
30. Warner M. A jolt of caffeine, by the can. New York Times. 2005 Nov 23; 2005.
31. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006 Mar;38(1):43–56. [PMC free article] [PubMed] 32. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry. 2008 May;165(5):553–555. [PMC free article] [PubMed] 33. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J. 2002 Dec;144(6):1065–1073. [PubMed] 34. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000 Dec 21;343(25):1826–1832. [PubMed] 35. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–698. [PubMed] 36. Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol. 2008 Jan 1;75(1):196–217. [PubMed] 37. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology. 2009;56 Suppl 1:3–8. [PMC free article] [PubMed] 38. Wee S, Carroll FI, Woolverton WL. A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology. 2006 Feb;31(2):351–362. [PubMed] 39. Chen R, Tilley MR, Wei H, et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333–9338. [PubMed] 40. Caine SB, Thomsen M, Gabriel KI, et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci. 2007 Nov 28;27(48):13140–13150. [PMC free article] [PubMed] 41. Kimmel HL, O'Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav. 2007 Jan;86(1):45–54. [PMC free article] [PubMed] 42. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991 Jul;14(7):299–302. [PubMed] 43. Filip M, Frankowska M, Zaniewska M, Golda A, Przegalinski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep. 2005 Nov–Dec;57(6):685–700. [PubMed] 44. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001 Jan;39(1):32–41. [PubMed] 45. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008 Jan 1;75(1):218–265. [PMC free article] [PubMed] 46. Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology. 2008 Jul;33(8):1779–1797. [PMC free article] [PubMed] 47. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006 Aug;26(8):1148–1156. [PubMed]
48. Angrist B, editor; Engel J, Oreland L, Ingvar DH, et al., editors. Clinical effects of central nervous system stimulants: a selective update. New York: Raven Press; 1987. Brain reward systems and abuse.
49. Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997 Jun 6;46(1–2):105–113. [PubMed] 50. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis. 2005;24(3):115–132. [PubMed] 51. O'Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. Med Clin North Am. 2005 Nov;89(6):1343–1358. [PubMed] 52. Gay GR. Clinical management of acute and chronic cocaine poisoning. Ann Emerg Med. 1982 Oct;11(10):562–572. [PubMed] 53. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005 Nov;2(4):194–199. [PubMed] 54. Myers MG, Rohsenow DJ, Monti PM, Dey A. Patterns of cocaine use among individuals in substance abuse treatment. Am J Drug Alcohol Abuse. 1995 May;21(2):223–231. [PubMed] 55. O'Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther. 2005 Oct;108(1):18–58. [PubMed] 56. Kalivas PW, Pierce RC, Cornish J, Sorg BA. A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol. 1998;12(1):49–53. [PubMed] 57. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction. 2000 Aug;95 Suppl 2:S91–S117. [PubMed] 58. Bonate PL, Swann A, Silverman PB. Context-dependent cross-sensitization between cocaine and amphetamine. Life Sci. 1997;60(1):PL1–PL7. [PubMed] 59. Mahoney JJ, 3rd, Kalechstein AD, De La Garza R, 2nd, Newton TF. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. Am J Addict. 2008 Mar–Apr;17(2):83–98. [PubMed] 60. Fasano A, Barra A, Nicosia P, et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend. 2008 Jul 1;96(1–2):178–182. [PubMed] 61. Hall W, Hando J, Darke S, Ross J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction. 1996 Jan;91(1):81–87. [PubMed] 62. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend. 1997 Mar 14;44(2–3):87–94. [PubMed] 63. Flaum M, Schultz SK. When does amphetamine-induced psychosis become schizophrenia? Am J Psychiatry. 1996 Jun;153(6):812–815. [PubMed] 64. Yui K, Ishiguro T, Goto K, Ikemoto S. Factors affecting the development of spontaneous recurrence of methamphetamine psychosis. Acta Psychiatr Scand. 1998 Mar;97(3):220–227. [PubMed] 65. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology. 1998 Apr;18(4):263–271. [PubMed] 66. Lim KO, Wozniak JR, Mueller BA, et al. Brain macrostructural and microstructural abnormalities in cocaine dependence. Drug Alcohol Depend. 2008 Jan 1;92(1–3):164–172. [PMC free article] [PubMed] 67. Yucel M, Lubman DI, Solowij N, Brewer WJ. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry. 2007 Dec;41(12):957–968. [PubMed] 68. Coffey SF, Dansky BS, Carrigan MH, Brady KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend. 2000 Jun 1;59(3):277–286. [PubMed] 69. Lago JA, Kosten TR. Stimulant withdrawal. Addiction. 1994 Nov;89(11):1477–1481. [PubMed]
70. Anthony JC, Warner LA, Kessler RC. Comparitive epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2:244–268.
71. Woody GE, Cottler LB, Cacciola J. Severity of dependence: data from the DSM-IV field trials. Addiction. 1993 Nov;88(11):1573–1579. [PubMed] 72. Gossop M, Griffiths P, Powis B, Strang J. Cocaine: patterns of use, route of administration, and severity of dependence. Br J Psychiatry. 1994 May;164(5):660–664. [PubMed] 73. Gorelick DA. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol. 1998;42:995–997. [PubMed]
74. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision ed. Washington, DC: American Psychiatric Association; 2000.
75. Agrawal A, Lynskey MT. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction. 2008 Jul;103(7):1069–1081. [PubMed] 76. Boghdadi MS, Henning RJ. Cocaine: pathophysiology and clinical toxicology. Heart Lung. 1997 Nov–Dec;26(6):466–483. quiz 484-465. [PubMed] 77. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation. 2001 Jan 30;103(4):502–506. [PubMed] 78. Gitman MD, Singhal PC. Cocaine-induced renal disease. Expert Opin Drug Saf. 2004 Sep;3(5):441–448. [PubMed] 79. Glauser J, Queen JR. An overview of non-cardiac cocaine toxicity. J Emerg Med. 2007 Feb;32(2):181–186. [PubMed] 80. Doctora JS, Williams CW, Bennett CR, Howlett BK. Rhabdomyolysis in the acutely cocaine- intoxicated patient sustaining maxillofacial trauma: report of a case and review of the literature. J Oral Maxillofac Surg. 2003 Aug;61(8):964–967. [PubMed] 81. Goodger NM, Wang J, Pogrel MA. Palatal and nasal necrosis resulting from cocaine misuse. Br Dent J. 2005 Mar 26;198(6):333–334. [PubMed] 82. Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol. 2007 Dec;19(6):578–585. [PubMed] 83. Phupong V, Darojn D. Amphetamine abuse in pregnancy: the impact on obstetric outcome. Arch Gynecol Obstet. 2007 Aug;276(2):167–170. [PubMed] 84. Williams JH, Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2007 Jun;16(4):243–253. [PubMed] 85. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol. 2000 Nov;7(6):595–606. [PubMed] 86. Warner EA. Cocaine abuse. Ann Intern Med. 1993 Aug 1;119(3):226–235. [PubMed] 87. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000 Winter;9(1):28–37. [PubMed] 88. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1556–1571. [PubMed] 89. Buffenstein A, Heaster J, Ko P. Chronic psychotic illness from methamphetamine. Am J Psychiatry. 1999 Apr;156(4):662. [PubMed] 90. Mello NK, Mendelson JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav. 1997 Jul;57(3):571–599. [PubMed] 91. Carey JC. Pharmacological effects on sexual function. Obstet Gynecol Clin North Am. 2006 Dec;33(4):599–620. [PubMed] 92. Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol. 2007 Sep 15;100(6):1040–1043. [PubMed] 93. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001 Aug 2;345(5):351–358. [PubMed] 94. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007 Feb;120(2):165–171. [PubMed] 95. Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med. 2001 Mar;7(2):43–61. [PubMed] 96. Wolff AJ, O'Donnell AE. Pulmonary effects of illicit drug use. Clin Chest Med. 2004 Mar;25(1):203–216. [PubMed] 97. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med. 2006 Jun–Jul;14(2):84–87. [PubMed] 98. Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987 Jul;1(2):67–76. [PubMed] 99. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989 Jan 27;261(4):561–565. [PubMed] 100. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002 Dec 1;186(11):1558–1564. [PubMed] 101. Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health. 1993 Aug;83(8):1144–1148. [PubMed] 102. Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med. 1994 Nov 24;331(21):1422–1427. [PubMed] 103. Fisher DG, Reynolds GL, Napper LE. Use of crystal methamphetamine, Viagra, and sexual behavior. Curr Opin Infect Dis. Feb;23(1):53–56. [PMC free article] [PubMed] 104. Stall R, Paul JP, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men's Health Study. Addiction. 2001 Nov;96(11):1589–1601. [PubMed] 105. Colfax G, Coates TJ, Husnik MJ, et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men. J Urban Health. 2005 Mar;82(1 Suppl 1):i62–i70. [PMC free article] [PubMed] 106. Halkitis PN, Mukherjee PP, Palamar JJ. Longitudinal modeling of methamphetamine use and sexual risk behaviors in gay and bisexual men. AIDS Behav. 2009 Aug;13(4):783–791. [PubMed] 107. Thiede H, Jenkins RA, Carey JW, et al. Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health. 2009 Apr;99 Suppl 1:S157–S164. [PubMed] 108. Semple SJ, Strathdee SA, Zians J, Patterson TL. Sexual risk behavior associated with co-administration of methamphetamine and other drugs in a sample of HIV-positive men who have sex with men. Am J Addict. 2009 Jan–Feb;18(1):65–72. [PMC free article] [PubMed] 109. Prestage G, Jin F, Kippax S, Zablotska I, Imrie J, Grulich A. Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. J Sex Med. 2009 Aug;6(8):2311–2320. [PubMed] 110. Sanchez TH, Gallagher KM. Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2006 May;42(1):95–100. [PubMed] 111. Ostrow DG, Plankey MW, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):349–355. [PMC free article] [PubMed] 113. Kulig JW. Tobacco, alcohol, and other drugs: the role of the pediatrician in prevention, identification, and management of substance abuse. Pediatrics. 2005 Mar;115(3):816–821. [PubMed]
114. Gynecology. Guidelines for Women's Health Care. 2nd edition ed. Washington, D.C.: 2002. ACoOa.
115. Sullivan E, Fleming M. Co-Chairs CP. Center for Substance Abuse Treatment SAaMHSA, ed. Rockville, MD: U.S. Department of Health and Human Services; 1997. A Guide to Substance Abuse Services for Primary Care Clinicians: Treatment Improvement Protocol (TIP) Series 24.
116. Zgierska A, Fleming MF. Screening and Brief Intervention. In: Ries RK, Fiellin DA, Miller SC, Saitz R, editors. Principles of Addiction Medicine. Fourth Edition ed. Wolters Kluwer Lippincott Williams andWilkins; 2009.
117. Barry KL. Center for Substance Abuse Treatment SAaMHSA, ed. Rockville, MD: U.S. Department of Health and Human Services; 1999. Brief Interventions and Brief Therapies for Substance Abuse: Treatment Improvement Protocol (TIP) Series 34.
118. Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med. 2005 May 9;165(9):986–995. [PubMed] 119. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;(2) CD004148. [PubMed] 120. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004 Apr 6;140(7):557–568. [PubMed] 121. Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend. 2009 Jan 1;99(1–3):280–295. [PMC free article] [PubMed] 122. Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005 Jan 7;77(1):49–59. [PubMed] 123. Baker A, Lee NK, Claire M, et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction. 2005 Mar;100(3):367–378. [PubMed] 124. Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry. 2009 May;22(3):263–268. [PMC free article] [PubMed] 125. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008 Feb;165(2):179–187. [PubMed] 126. Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998 May;93(5):713–727. [PubMed] 127. Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998 Oct;66(5):832–837. [PubMed] 128. Monti PM, Rohsenow DJ, Michalec E, Martin RA, Abrams DB. Brief coping skills treatment for cocaine abuse: substance use outcomes at three months. Addiction. 1997 Dec;92(12):1717–1728. [PubMed] 129. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse. Sep 1991;17(3):229–247. [PubMed] 130. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008 May;27(3):309–317. [PubMed]
131. Higgins ST, Tidey JW, Rogers RE. Contingency Management and the Community Reinforcement Approach. In: Ries RK, Fiellin DA, Miller SC, Saitz R, editors. Principles of Addiction Medicine. Fourth Edition ed. Wolters Kluwer Lippincott Williams andWilkins; 2009.
132. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000 Feb 1;58(1–2):55–66. [PubMed] 133. Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006 Feb;101(2):192–203. [PubMed] 134. Prendergast ML, Podus D, Chang E, Urada D. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend. 2002 Jun 1;67(1):53–72. [PubMed] 135. Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav. 2003 Mar;17(1):73–82. [PMC free article] [PubMed] 136. Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol. 2000 Feb;68(1):64–72. [PubMed] 137. Petry NM, Alessi SM, Hanson T. Contingency management improves abstinence and quality of life in cocaine abusers. J Consult Clin Psychol. 2007 Apr;75(2):307–315. [PubMed] 138. Secades-Villa R, Garcia-Rodriguez O, Higgins ST, Fernandez-Hermida JR, Carballo JL. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. J Subst Abuse Treat. 2008 Mar;34(2):202–207. [PubMed] 139. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006 Feb;101(2):267–274. [PubMed] 140. Roll JM, Petry NM, Stitzer ML, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006 Nov;163(11):1993–1999. [PubMed] 141. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005 May 9;78(2):125–134. [PubMed] 142. Lima MS, Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev. 2003;(2) CD002950. [PubMed] 143. Elkashef A, Holmes TH, Bloch DA, et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction. 2005 Mar;100 Suppl 1:91–101. [PubMed] 144. Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse. 2007;33(3):367–378. [PubMed] 145. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb;63(2):219–228. [PubMed]